CBIO

Crescent Biopharma, Inc. Common Stock

13.92

USD

+0.27

+1.98%

Nov 10, 15:59 UTC -5

Closed

After-Market

13.96

+0.04

+0.25%

Crescent Biopharma, Inc. Common Stock (CBIO) Earnings

CBIO Earnings Reports

Positive Surprise Ratio

CBIO beat 32 of 41 last estimates.

78%

Next Report

Date of Next Report

Feb 24, 2027

Estimate for Q4 26 (Revenue/ EPS)

$318.75K

-$0.75

Implied change from Q3 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

-97.06%

+38.89%

Crescent Biopharma, Inc. Common Stock earnings per share and revenue

On Nov 06, 2026, CBIO reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.73 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 318.75 thousand, with a --% difference.

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.75 USD, with revenue projected to reach 318.75 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Crescent Biopharma, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Crescent Biopharma, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.

How did the market react to Crescent Biopharma, Inc. Common Stock's Q3 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Crescent Biopharma, Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 24, 2027.

What are the forecasts for Crescent Biopharma, Inc. Common Stock's next earnings report?

Based on -- analysts, Crescent Biopharma, Inc. Common Stock is expected to report EPS of -$0.75 and revenue of $318.75K for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.